Janssen announces U.S. FDA approval of Invega Hafyera
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
PPH is associated with almost 20 per cent of maternal mortality in India
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
The module offers the first preclinical laboratory information system of its kind that is fully integrated into the digital pathology workflow and provides efficient pathological studies of whole slides
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
Subscribe To Our Newsletter & Stay Updated